New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease

Mounting evidence suggests that diabetes mellitus (DM) is associated with mild cognitive impairment (MCI), vascular dementia and Alzheimer's disease (AD). Biological, clinical and epidemiological data support a close link between DM and AD. Increasingly, studies have found that several antidiabetic agents can promote neurogenesis, and clinically ameliorate cognitive and memory impairments in different clinical settings. Data has shown that these antidiabetic drugs positively affect mitochondrial and synaptic function, neuroinflammation, and brain metabolism. Evidence to date strongly suggests that these antidiabetic drugs could be developed as disease-modifying therapies for MCI and AD in patients with and without diabetes.

Effect of mild hypothermia on breast cancer cells adhesion and migration

To explore the effect of mild hypothermia (35ºC) on breast cancer cells adhesion to vascular endothelial cells, a parallel plant flow chamber was used to observe the adhesion of human breast cancer cells MDA-MB-231 to endothelial cells Eahy926 under physiological flow at 35ºC and 37ºC, as well as the role of intercellular adhesion molecule 1 (ICAM-1) in this process. Further, the effect of mild hypothermia (35ºC) on migration of MDA-MB-231 was also studied. Our results show that mild hypothermia can inhibit the adhesion of tumor cells to endothelial cells and ICAM-1 plays an important role in this process. However, mild hypothermia inhibits breast cancer cell adhesion in a way independent on the change of ICAM-1 expression under our experimental conditions. Mild hypothermia can weaken the chemotaxis of breast cancer cells while it has no obvious effect on unidirectonal migration capacity. These results suggest that mild hypothermia could be used as a potentially adjunct treatment combined with surgery to decrease tumor cell adhesion and migration.

Wortmannin inhibits proliferation and induces apoptosis of MCF-7 breast cancer cells

OBJECTIVE

The present study aimed to explore the effects of wortmannin in the proliferation and apoptosis of human breast cancer MCF-7 cells.

METHODS

The authors treated cells with 0, 1, 6.25, 12.5, 25, and 50 nM wortmannin for 24, 48, and 72 hours. Inhibition of proliferation was measured by cell counting kit-8 assay (CCK8). Apoptosis was detected with Annexin V-fluorescein isothiocyanate/propidium iodide double staining by flow cytometry. Additionally, expression of proteins involved in the PI3K pathway, specifically total Akt, phosphorylated Akt (p-Akt), and NF-kappaB was detected by Western blotting following 24 hours of wortmannin exposure.

RESULTS

Higher doses (6.25, 12.5, 25, and 50 nM) of wortmannin significantly inhibited proliferation of MCF-7 cells after 24, 48, and 72 hours of exposure compared with control MCF-7 cells incubated with DMSO alone in DMEM (p < 0.05). This inhibition increased with concentration and duration of treatment. Similarly, wortmannin at 6.25, 12.5, 25, and 50 nM concentrations significantly increased apoptosis of MCF-7 cells following 24 hours of exposure (p < 0.05). Western blotting revealed that increasing concentrations of wortmannin (6.25, 12.5, 25, and 50 nM, 24 hours) increasingly reduced expression of p-Akt and NF-kappaB; however, expression of total Akt was unaffected at any concentration of wortmannin.

CONCLUSIONS

Wortmannin inhibits proliferation and induces apoptosis of MCF-7 cells in a dose and time-dependent manner, likely through down-regulation of PI3K/Akt signaling and NF-kappaB protein expression.